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of Medicine, Keelung, Taiwan; 4Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, TaiwanSummary adverse sequelae, including cirrhosis and hepatocellular carci-Following development of liver cirrhosis in patients with chronic
hepatitis B, liver diseasemay continue to progress and decompen-
sation or hepatocellular carcinoma (HCC) may occur, especially in
those with active viral replication. Decompensation may manifest
with jaundice, ascites, variceal bleeding or hepatic encephalopa-
thy. Earlier studies have shown that the prognosis of decompen-
sated cirrhosis is usually poor with a 5-year survival rate at 14–
35%under conventional standard of care. The approval of oral anti-
viral agents has greatly improved the prognosis, as demonstrated
in several cohort studies and randomized clinical trials involving
therapy with lamivudine, adefovir dipivoxil, entecavir, telbivu-
dine, or tenofovir disoproxil fumarate. Oral antiviral agents are
effective in restoring liver function and improving survival in
patients with decompensated cirrhosis especially if therapy is ini-
tiated early enough. These agents are generally well tolerated
without signiﬁcant side effects. However, their preventive effect
in HCC development has yet to be convincingly demonstrated.
Given their known resistance proﬁles, entecavir and tenofovir
should be considered as the ﬁrst-line therapy for patients with
HBV-related decompensated cirrhosis.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Chronic hepatitis B virus (HBV) infection is a serious health prob-
lem because of its worldwide distribution and its potentialJournal of Hepatology 20
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fumarate.noma (HCC) [1,2]. It was estimated that more than 200,000 and
300,000 chronic HBV carriers worldwide die of liver cirrhosis
and HCC, respectively, each year [3]. Since HBV replication,
reﬂected in the presence of serum hepatitis B e antigen (HBeAg)
and/or HBV DNA P2000 IU/ml, may persist after the develop-
ment of cirrhosis [4], liver disease may continue to progress
and hepatic decompensation or HCC may occur. In recent years,
remarkable advances have been achieved in the understanding
of the natural course after the development of cirrhosis, in the
general management of its complications and in the antiviral
treatment of this patient population. This review summarizes
the advances in general and the beneﬁts of current antiviral ther-
apy in particular.Natural course after the development of cirrhosis
A substantial proportion of patients with cirrhosis have active
HBV replication. A prospective study on cirrhosis detected during
long-term follow-up of patients with chronic hepatitis B (CHB) in
Taiwan showed that 30% of the 93 patients were seropositive for
HBeAg and 73% had a serum HBV DNA level >10,000 copies/ml
(2000 IU/ml) at the time of cirrhosis detection with a mean age
of 43.6 (24–69) years. During a follow-up period of 12–246 (med-
ian 97, mean 102 ± 60) months, hepatitis ﬂare, HBeAg serocon-
version, and hepatitis B surface antigen (HBsAg) loss occurred
in 32 (34%) of 93, 15 (54%) of 28, and 12 (13%) of 93 patients,
respectively; and hepatic decompensation, HCC, and mortality
occurred in 12 (13%), 21 (23%), and 11 (12%) patients, respec-
tively [4]. Two earlier studies from Europe showed that 35%-
55% of patients with compensated cirrhosis were HBeAg positive
[5,6] and 48% of patients in one study were HBV DNA positive (by
hybridization) at presentation [6]. HBeAg positivity at presenta-
tion was associated with a worse survival and HBeAg or HBV
DNA seroclearance during follow-up was associated with a better
survival. The cumulative probability of survival at 5 years was
84% for both studies [5,6]. These studies suggest that at least
30–70% of the patients still have active viral replication at pre-
sentation of compensated cirrhosis, and that active viral replica-
tion is associated with continued liver disease progression and
decreased survival over time. By contrast, concurrent hepatitis
C virus (HCV) or hepatitis D virus (HDV) infection in HBV-related12 vol. 57 j 442–450
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cirrhosis may suppress HBV replication despite continuing liver
disease progression [7].
Development of HCC
Cirrhosis is the most important risk factor for HCC development.
Risk factors for developing HCC in HBV-related cirrhosis include
older age, male gender, severity of liver disease, active viral rep-
lication during follow-up, viral genotype, viral mutants, concur-
rent HCV or HDV infection, alcohol intake, and aﬂatoxin
exposure [8]. The risk of HCC in cirrhotic patients is higher in East
Asia than in the West, possibly because of earlier acquisition of
HBV infection and a longer duration of disease. Combining all
data from published studies, the 5-year cumulative incidence of
HCC in cirrhotic patients was reported to be 17% in East Asia
and 10% in the West [7]. A population-based cohort study in Tai-
wan showed that baseline HBV DNA level >104 copies/ml was the
strongest independent predictor of HCC at a dose-dependent
manner after adjustment for age, sex, smoking, alcohol, HBeAg
status, and serum ALT level. However, the predictive role of base-
line HBV DNA level in HCC development in the subgroup of
patients with cirrhosis was not reported [9]. Several clinical stud-
ies in patients with cirrhosis showed no signiﬁcant correlation
between HBV DNA level or HBeAg status and the development
of HCC [4,10,11]. However, two studies from Japan showed a sig-
niﬁcant correlation between baseline HBV DNA level and the risk
of HCC and that persistence of high HBV DNA level (>5000 copies/
ml) during follow-up was associated with an increased risk of
HCC development [12,13]. The Taiwan study showed that persis-
tent HBeAg seropositivity was related to HCC development with
marginal signiﬁcance (p = 0.062) in multivariate analysis [4].
The controversies on the role of baseline viral load and persis-
tence of viral replication in the development of HCC in patients
with cirrhosis require further study.
Development of hepatic decompensation
Decompensation usually presents with at least one episode of
ascites, jaundice, hepatic encephalopathy (HE) or variceal bleed-
ing [5,10]. Several cohort studies have shown that 2–5% of
patients with HBV-related compensated cirrhosis developed
decompensation each year [4,10,11]. This can develop insidiously
or as a complication of acute hepatitis ﬂare [14,15]. The latter was
demonstrated in a study showing that hepatic decompensation
developed in 14% of cirrhotic patients who experienced hepatitis
ﬂares [14]. These two modes of hepatic decompensation have not
been clearly differentiated and compared in terms of prognosis.
One study in 161 patients showed that the risk of hepatic decom-
pensation during a median follow-up period of 6.6 years was
4-fold higher in HBV DNA positive patients (13–18%) than in
HBeAg negative/HBV DNA negative patients (4%, p = 0.04) at
entry [11]. Another study of 93 newly developed cirrhotic
patients showed that persistent HBeAg seropositivity was signif-
icantly (p = 0.035) associated with the development of decom-
pensation and the risk of hepatic decompensation during a
mean follow-up period of 102 months was 6-fold higher in
persistently HBeAg positive patients than in patients who were
seronegative for HBeAg at entry [4]. These data suggest that sero-
positivity for HBeAg or HBV DNA at presentation or HBeAg persis-
tence, reﬂecting active HBV replication, in compensated cirrhosis
is an important factor contributing to further disease progression.Journal of Hepatology 201Other than active HBV replication, other hepatitis virus(es)
superinfections in HBV-related cirrhotic patients may increase
the development of decompensation during the acute phase
[16,17] and could be a cause of decompensation during the
chronic phase of HCV or HDV superinfection [7,17].Natural history after the ﬁrst episode of hepatic
decompensation
Earlier European studies showed that the ﬁrst episode of decom-
pensation most commonly presented with ascites and the prog-
nosis after the development of decompensation was poor, with
a 5-year survival rate of 14–35% [5,10,11]. The presenting fea-
tures of decompensated cirrhosis, its subsequent survival and
prognostic indicators were investigated in two Asian studies. A
retrospective cohort study involved 96 patients with a median
follow-up duration of 3.5 years following the onset of hepatic
decompensation. At presentation, the mean age was 54 years
and 24% of the patients were HBeAg seropositive. The presenting
features were ascites (70%), variceal bleeding (34.3%), jaundice
(26%), spontaneous bacterial peritonitis (SBP, 7.3%), and HE
(5.2%). Twenty-nine percent of the patients had more than one
feature of decompensation. HCC developed in 24 (25%) patients
during a median duration of 3 (0.45–7.9) years. The overall 2-year
survival rate was 80% after the onset of decompensation. The
causes of death were hepatic failure (52.9%), HCC (29.4%), variceal
bleeding (5.9%), and SBP (4.4%). HE and hypoalbuminemia
(62.8 g/dl) were signiﬁcant prognostic factors. HBeAg status
was not a signiﬁcant prognostic factor although serum HBV
DNA level was not examined in this study [18]. Another retro-
spective–prospective cohort study enrolled 102 untreated
decompensated cirrhotics with a mean follow-up duration of
46 months. The mean age was 46 years and 28% of the patients
were HBeAg seropositive. The presenting features were ascites
(63%), variceal bleeding (37%), and HCC (10%). HCC developed
in 3% during follow-up. During a median follow-up duration of
13 months, 22 patients died and Kaplan–Meier survival analysis
showed a 5-year survival rate of 19%. The causes of death were
hepatorenal syndrome (HRS, 32%), variceal bleeding (23%), HCC
(28%), liver failure (9%), and HE (9%). Initial decompensation with
ascites and development of sepsis with features of systemic
inﬂammatory response were independent predictors of death
[19]. Three of the above ﬁve studies examined the impact of
the HBeAg status on the survival but did not ﬁnd signiﬁcant asso-
ciation [5,18,19]. None of the studies assessed the predictive role
of baseline HBV DNA level in patient survival. Therefore, the
prognostic signiﬁcance of HBV viremia at the decompensated
stage of cirrhosis remains to be studied.
The natural history of HBV-related cirrhosis and decompen-
sated cirrhosis is summarized in Fig. 1 and Table 1.General management of patients with decompensated
cirrhosis
Upon detection or presentation, patients need to be evaluated
carefully. The evaluations include liver function status, complete
blood cell counts, cause(s) of decompensation (HBV, HCV or
HDV), the presence and degree of varices, ascites with or without
peritonitis, and HE. The Child–Turcotte–Pugh (CTP) score and2 vol. 57 j 442–450 443
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Fig. 1. Natural history of hepatitis B virus (HBV)-related cirrhosis. /yr, per year.
ReviewModel for End Stage Liver Disease (MELD) score are the two liver-
speciﬁc scoring systems that have been used to assess disease
severity in patients with cirrhosis. The CTP score was originally
developed to predict post-operative mortality in bleeding alco-
holic cirrhotics undergoing portal-systemic shunt surgery [20].
Although it predicts 1-year survival and post-surgical risks of
complications, it does not predict short-term mortality [21].Table 1. Natural history of HBV-related decompensated cirrhosis.
Study,
[Ref.]
de Jongh et al.,
[5]
Fattovich et al.,
[10]
Number of patients 21 88
Age (yr) 46a n.r.
Follow-up period (yr) 4.3b n.r.
Presenting features
Ascites, (%) 62 30
Variceal bleeding, (%) n.r. 8
Jaundice, (%) 48 17
SBP, (%) n.r. n.r.
HE, (%) 19 n.r.
HCC, (%) n.r. 0
More than one feature, (%) n.r. 47
HBeAg/HBV DNA positive, (%) 52/n.r. n.r.
HCC development , (%) n.r. n.r.
Survival
1-year, (%) 70 58
3-year, (%) 35 40
5-year, (%) 14 35
Cause of death
Hepatic failure, (%) n.r. n.r.
HCC, (%) n.r. n.r.
Prognostic factors n.r. n.r.
Alb, albumin; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HE, hepatic enceph
inﬂammatory response syndrome.
aMedian.
bMean.
cTwo-year survival rate.
444 Journal of Hepatology 201The MELD score was initially developed to predict short-term
mortality in patients undergoing transjugular intrahepatic porto-
systemic shunt [22]. It was later used to predict 3-month mortal-
ity in patients with cirrhosis, irrespective of cause, and has been
adopted to prioritize organ allocation for liver transplantation in
the United States since 2002 [23,24]. A major feature of the MELD
scoring system is the inclusion of renal function in the model.
Renal dysfunction commonly occurs during the course of disease
progression in cirrhosis and has been shown to have a prognostic
impact on survival [25].
Standard of care in patients with decompensation according
to their presentations, including control of ascites, bleeding,
infection or encephalopathy, should be instituted promptly and
adequately [26]. Surveillance of HCC and timely consultation or
referral for liver transplantation is also mandatory [27,28]. For
decompensation due to other hepatitis viral superinfections,
anti-HBV therapy is useless and liver transplantation is the more
immediate option.Antiviral drug therapy
Antiviral therapy should be initiated as soon as the diagnosis has
been established. The immediate goal of antiviral therapy is to
improve hepatic dysfunction and rescue the patients from mor- Fattovich et al., 
[11]
Hui et al.,
[18]
Das et al.,
[19]
33 96 102
n.r. 54b 46b
n.r. 3.5a 1.1a
49 70 63
9 34.3 37
12 26 8
n.r. 7.3 n.r.
0 5.2 0
0 0 10
30 29 n.r.
n.r. 24/n.r. 28/n.r.
n.r. 25 3
71 90 n.r.
40 80c n.r.
28 n.r. 19
64 52.9 9
n.r. 29.4 28
n.r. HE, 
Alb ≤2.8 g/dl
ascites 
presentation, 
sepsis with SIRS
alopathy; n.r., not reported; SBP, spontaneous bacterial peritonitis; SIRS, systemic
2 vol. 57 j 442–450
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tality. The clinical improvement in some wait-listed patients with
antiviral therapy can result in their withdrawal from the trans-
plant list [27–31].
The use of interferon alfa in patients with HBV-related decom-
pensated cirrhosis can precipitate clinical decompensation and
increase the risk of bacterial infection, even with low doses. In
the era of nucleos(t)ide analogue (Nuc), interferon is contraindi-
cated in this patient population.
Currently, lamivudine (LAM), adefovir dipivoxil (ADV), enteca-
vir (ETV), telbivudine (LdT), and tenofovir disoproxil fumarate
(TDF) have been approved for CHB therapy. All of these Nucs
are competitive inhibitors of the HBV DNA polymerase via com-
petition with the incorporation of the natural endogenous intra-
cellular nucleotides in nascent HBV DNA and cause DNA chain
termination. All of these Nucs have activities conferring biochem-
ical, virological, and serological improvement in CHB patients
[29–31]. They can also retard the progression of ﬁbrosis and
reverse ﬁbrosis and cirrhosis [32–34]. Long-term therapy may
also prevent hepatic decompensation in patients with advanced
ﬁbrosis and cirrhosis [35]. More importantly, it has demonstrated
efﬁcacy in rescuing patients with decompensated CHB since year
2000 [15]. The number of candidates on the waiting list of liver
transplantation for HBV-related decompensated liver disease in
the United States has decreased signiﬁcantly since then [36].
LAM therapy has the longest history of extensive evaluation.
The efﬁcacy and safety of these drugs are summarized below.
Lamivudine
LAM is an L-nucleoside analogue and is the ﬁrst oral agent
licensed for treatment of CHB. It is generally safe and well toler-
ated. Earlier studies involving a relatively small number (13–35)
of patients with decompensated cirrhosis consistently showed
signiﬁcant increase in serum albumin, decrease in serum biliru-
bin and decrease in CTP score as compared to baseline [37–40].
In decompensated wait-listed patients for liver transplantation,
a study showed that LAM therapy improved biochemical and
virological proﬁles and survival in non-transplanted patients,
and also protected against HBV reinfection with improved sur-
vival in transplanted patients [41]. Another study showed that
liver transplantation was performed in a signiﬁcantly smaller
proportion of LAM-treated patients than in controls (35% vs.
74%, p = 0.04), and time to death or liver transplantation was also
signiﬁcantly longer in LAM-treated patients [42].
The severity of liver disease at the time of LAM treatment ini-
tiation may have an impact on the time it takes for liver functions
to recover. A small study showed that patients of Child class B
needed shorter time to achieve a 2-point reduction in CTP score
(5.9 vs. 14 months, p <0.001) and to gain a 0.5 g/dl increment in
albumin (5.8 vs. 14 months) than patients of Child class C [43].
These results suggest that patients with decompensated cirrhosis
should receive antiviral therapy as early as possible to allow a
better chance of functional recovery.
Not all patients with decompensated cirrhosis survived LAM
treatment; it is thus important to identify factors predictive of
early death following the institution of LAM therapy to allow
timely intervention of liver transplantation to prevent mortality.
A prospective multicenter study involving LAM therapy in 154
North American patients with decompensated cirrhosis for a
mean duration of 16 months showed that 32 patients (21%) died
of liver failure and 78% of the deaths occurred within the ﬁrstJournal of Hepatology 2016 months of therapy, with an estimated actuarial 3-year survival
of 88% in patients who survived beyond 6 months. Elevated base-
line serum bilirubin and creatinine levels and detectable baseline
serum HBV DNA (by the bDNA assay with a lower detection limit
of 0.7 MEq/ml) were found to be independent predictors of 6-
month mortality during LAM therapy. Early virological response
with undetectable serum HBV DNA at 8 weeks of therapy did
not correlate with survival [44]. These results indicate that the
severity of liver disease at the time of initiating antiviral therapy
is a more relevant determinant of early mortality than early viro-
logical response, and should be used to guide patient prioritiza-
tion for liver transplantation. These results again suggest that
antiviral therapy must be initiated as early as possible and before
the decompensation becomes too severe to be rescued.
It was not clear whether some of the patients in the afore-
mentioned studies evaluating the beneﬁt of LAM therapy in
decompensated cirrhosis actually had developed hepatic decom-
pensation due to a hepatitis ﬂare. Nonetheless, several studies
on the efﬁcacy of LAM in patients with hepatic decompensation
during acute hepatitis ﬂare of CHB have included small number
of patients with cirrhosis. All showed similar therapeutic out-
comes, including mortality rate, as compared with those with-
out underlying cirrhosis [45–48]. One study showed that
initiation of LAM therapy even before the onset of HE did not
substantially improve the short-term mortality in comparison
with untreated historical controls if the baseline serum bilirubin
had already increased over 6 mg/dl with a prothrombin <40%
[47], suggesting that suppression of HBV replication at this stage
of severe hepatic necroinﬂammation may be too late to abort
the heightened ongoing immune-mediated liver injury. A study
in patients with acute exacerbation and decompensation from
Taiwan, including 19 patients with cirrhosis, showed that initia-
tion of LAM therapy in patients with a bilirubin level below
20 mg/dl was signiﬁcantly associated with a lower mortality rate
(0% vs. 20% in untreated historical controls) but not in patients
with a serum bilirubin level increased over 20 mg/dl (67% vs.
82% in untreated historical controls) [46]. These results also sug-
gest that oral antiviral therapy should be initiated as early as pos-
sible, in the setting of HBV-related acute exacerbation with
ensuing or overt hepatic decompensation, and the lower the bili-
rubin and creatinine the better the prognosis in cirrhotic patients.
Whether LAM therapy decreases the risk of HCC in patients
with decompensated cirrhosis remains controversial. In a large
randomized placebo-controlled study, LAM therapy for a median
duration of 32.4 months was shown to reduce the incidence of
HCC and decompensation in patients with advanced ﬁbrosis or
compensated cirrhosis (hazard ratio 0.49, p = 0.047). However,
no protective effect was found in patients whose CTP increased
over 7 at the start of drug therapy [35]. Two recent studies
showed that virological suppression with LAM did not signiﬁ-
cantly reduce the incidence of HCC in Child class B and C patients
[49,50]. One possible explanation is that cirrhosis is the most
important risk factor for HCC as chromosomal aberrations have
occurred in cirrhotic nodules [51], and some of the genetic events
occurring in HCC may have been present before the initiation of
antiviral therapy. Of note, the case number of the patients with
decompensated cirrhosis included was small (N = 56) in one
study [50] and the median follow-up durations were short (3.0
and 2.7 years, respectively). It remains to be clariﬁed whether
Nuc therapy for a longer duration effectively reduces the inci-
dence of HCC in patients with decompensated cirrhosis.2 vol. 57 j 442–450 445
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LAM was well-tolerated without signiﬁcant side effects in all
studies. With the approval of high genetic barrier Nucs, ETV
and TDF, LAM should not be considered as the ﬁrst-line therapy
in patients with decompensated cirrhosis because of its high rate
of resistance over long-term use [29–31]. Nevertheless, lessons
learned from LAM therapy in this patient population may be
applied in the therapy with other Nucs.
Adefovir dipivoxil
ADV is an acyclic nucleotide analogue of adenosine monophos-
phate and is active against both wild type and LAM-resistant
mutants of HBV. ADV was used at 10 mg daily as a rescue therapy
in a study involving 128 wait-listed patients with decompensated
cirrhosis who failed LAM therapy and 196 patients with recurrent
hepatitis B after liver transplantation. After 48 weeks of treat-
ment, 81% and 76% of the wait-listed and 34% and 49% of the
post-transplant patients achieved undetectable HBV DNA
(<400 copies/ml) and normal ALT, respectively. The CTP score
improved in over 90% of patients in both cohorts. One-year sur-
vival was 84% for the wait-listed and 93% for the post-transplant
patients [52]. In a long-term follow-up study of the 226 wait-
listed patients and 241 post-transplant patients with recurrent
hepatitis B due to LAM-resistant HBV, ADV was used for a median
duration of 39 and 99 weeks, respectively. Fifty-nine percent and
65% of the wait-listed and 40% and 65% of the post-transplant
patients achieved undetectable HBV DNA (<1000 copies/ml) after
48 and 96 weeks of therapy, respectively. After 48 weeks of treat-
ment, liver function improved in 50%-80% of both patient groups.
Kaplan–Meier estimates of survival for the wait-listed and post-
transplant patients were 86% and 91% at 48 weeks, and 78%
and 88% at 96 weeks, respectively. ADV was discontinued due
to renal adverse events in 4% of the patients [53].
The efﬁcacy and safety of ADV as a ﬁrst-line therapy in
patients with decompensated cirrhosis have also been demon-
strated (see ETV section). Although ADV has a better resistance
proﬁle than LAM, its relatively slow HBV DNA suppression and
potential risk of drug resistance or renal toxicity remain a con-
cern for its routine use as a ﬁrst-line therapy in this patient
population.
Entecavir
ETV is a deoxyguanosine analogue that belongs to the cyclopen-
tane group. It has a very potent activity against wild type HBV but
a weaker activity against LAM-resistant HBV. There are several
case series studies using ETV therapy in decompensated patients.
A Korean study prospectively compared the efﬁcacy of ETV
0.5 mg daily in 70 patients with decompensated cirrhosis and
144 patients with compensated CHB. They found no signiﬁcant
differences between groups in mean HBV DNA changes, the pro-
portion of patients with undetectable HBV DNA or ALT normali-
zation, rates of HBeAg seroconversion or HBeAg loss after 6 or
12 months of treatment. Of the 55 decompensated patients trea-
ted for >12 months, the CTP score and the MELD score improved
signiﬁcantly after 12 months of treatment with 49% showing a
decrease of CTP score P2 points and 66% achieving CTP class A
status. The 2-year cumulative rates of HCC and death or liver
transplantation were 6.9% and 17%, respectively [54]. A study
from Hong Kong evaluated the efﬁcacy of ETV in 36 patients with
severe acute exacerbation of CHB (ﬁve with cirrhosis), in compar-446 Journal of Hepatology 201ison with a historical control group of 117 patients (25 with cir-
rhosis) treated with LAM. However, patients in the ETV group
were signiﬁcantly older, had lower ALT level, and female domi-
nant. The ETV group had higher mortality in cirrhotic patients
(2 of 5 or 40% vs. 1 of 25 or 4%, p = 0.064) by week 48. However,
further analyses showed that the presence of cirrhosis was not
associated with mortality [48].
A randomized, open-label, multicenter trial was conducted to
assess the safety and efﬁcacy of ETV 1.0 mg as compared to ADV
10 mg daily for 96 weeks in 191 patients with CTP scoreP7 [55].
As a primary efﬁcacy end point, ETV showed a greater mean
reduction in serum HBV DNA from baseline than ADV (4.48
vs. 3.40 log10 copies/ml, p <0.0001) at 24 weeks of treatment.
This difference persisted at all time points through week 48. A
signiﬁcantly greater proportion of ETV-treated patients showed
HBV DNA <300 copies/ml at 24 (49% vs. 16%) and 48 weeks
(57% vs. 20%), and ALT normalization at 24 (59% vs. 39%) and
48 weeks (63% vs. 46%) than ADV-treated patients. HBeAg sero-
conversion rates were similar between groups (6% vs. 10%).
Among ETV- and ADV-treated patients, a reduction of P2 points
in the CTP score occurred in 35% and 27% of patients and mean
reductions from baseline in MELD scores were 2.6 and 1.7 at
week 48. Cumulative HCC and death rates at week 48 were 12%
and 23% for ETV, respectively, and 20% and 33% for ADV, respec-
tively. The 30-day mortality was 2% for ETV and 4% for ADV.
Adverse event rates were comparable between groups. Rates of
serum creatinine increase P0.5 mg/dl from baseline were 17%
for ETV and 24% for ADV. No patients showed resistance in either
group at week 48. Although ETV showed superior virological and
biochemical improvements over ADV, it did not translate into
parallel improvements in hepatic function, HCC occurrence or
mortality, at least at 48 weeks of therapy. A follow-up of this
cohort is warranted to show whether more potent HBV DNA
suppression early on treatment leads to a better long-term
outcome.
A study from Germany reported that ﬁve of 16 patients with
HBV-related cirrhosis developed lactic acidosis between 4 and
240 days after starting ETV treatment [56]. All ﬁve patients
who developed lactic acidosis had a baseline MELD score P22,
thus the MELD score was suggested to be a predictor of the risk
of lactic acidosis in patients receiving ETV treatment. However,
lactic acidosis was reported in only one subject with a baseline
MELD score of 21 on day 1293 of treatment among the 99 ETV
treated patients in the trial comparing ETV with ADV in patients
with decompensated cirrhosis, and the event resolved with con-
tinued ETV treatment [55]. Lactic acidosis was not reported in
any of the 70 patients in the Korean study [54] or ﬁve patients
in the Hong Kong study [48]. Since severe decompensated liver
disease per se is at risk of lactic acidosis, monitoring this possible
lethal complication during Nuc therapy in patients with a high
MELD score is needed.
Tenofovir disoproxil fumarate
TDF is an acyclic nucleotide analogue and is structurally similar
to ADV. It is active against both wild type and LAM-resistant
mutants of HBV and is superior to ADV in HBeAg-negative and
HBeAg-positive treatment-naïve CHB patients. It also demon-
strated potent antiviral activity in patients with suboptimal
response to ADV, mostly with prior LAM exposure. A subgroup
analysis of the cirrhotic patients in the HBeAg-negative and2 vol. 57 j 442–450
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HBeAg-positive registration trials showed similar efﬁcacy and
safety to non-cirrhotic patients at 96 weeks of treatment [57].
A randomized, double-blind, multicenter trial assessed the
safety of TDF 300 mg/day (N = 45) or a ﬁxed-dose combination
of FTC/TDF 200 mg/300 mg per day (N = 45) as compared with
ETV 0.5 or 1.0 mg/day (N = 22) for 168 weeks in CHB patients
with current or past history of decompensation. Their baseline
CTP scores were 7–12 with a median of 7 and a median baseline
MELD score of 10 (5–13) [58]. At week 48, tolerability failure
rates were 6.7%, 4.4% and 9.1%, respectively. Rates of conﬁrmed
serum creatinine increaseP0.5 mg/dl from baseline or conﬁrmed
serum phosphorus <2 mg/dl were 8.9%, 6.7%, and 4.5%, respec-
tively. The proportions of patients with HBV DNA <400 copies/
ml were 70.5%, 87.8%, and 72.7%, respectively. The proportions
of patients with ALT normalization were 57%, 76%, and 55%,
respectively. HBeAg seroconversion rates were 21%, 13%, and
0%, respectively. A reduction of P2 points in the CTP score
occurred in 25.9%, 48%, and 41.7% of patients, respectively, and
the median reductions from baseline in the MELD score were
2.0, resulting in a median MELD score of 8 at week 48 in all three
groups. There were two deaths in each group, considered to be
due to disease progression. No patients developed resistance to
any study drug. Thus, all treatments were well tolerated with
virological, biochemical, and clinical improvements in this
patient population. Combining two TDF-containing arms, Grade
3 or 4 adverse effect was less common (20% vs. 53%) and none
of the patients with a baseline CTP score 69 died, as compared
with those having CTP score >9 (unpublished data). These again
suggest that treatment should be started early and before CTP
score rises over 9. Although not powered to compare the efﬁcacy,
TDF/FTC combination as Truvada seems to have the best thera-
peutic outcomes. It would be interesting to compare the long-
term efﬁcacy and resistance proﬁles across arms to evaluate the
role of combination therapy in this patient population.
A small randomized, double-blind, placebo-controlled study
from India evaluated the efﬁcacy of TDF at 300 mg/day in
patients with acute-on-chronic liver failure due to spontaneous
reactivation of HBV, including some patients with cirrhosis [Ishak
ﬁbrosis score 3 (2–6)] but the number of cirrhotic patients was
not reported [59]. At admission, patients in the TDF group
(N = 14) and the placebo group (N = 13) were severely ill (biliru-
bin: 24.5 vs. 18.2 mg/dl, CTP score: 11 vs. 11, and MELD score: 27
vs. 25). As expected, the cumulative survival rate at 3 months was
signiﬁcantly better in the TDF group (57% vs. 15%). Fifteen of the
17 deaths occurred due to progressive liver failure. The TDF-trea-
ted group showed a signiﬁcant improvement from baseline in the
CTP and MELD scores and signiﬁcant decline in HBV DNA levels.
More than 2-log reduction in HBV DNA levels at 2 weeks of treat-
ment was the only independent predictor of survival. Hence,
rapid suppression of HBV DNA despite at a time when the height-
ened immune response is ongoing can stabilize or halt disease
progression, and thereby improves prognosis. Although this
study clearly demonstrated the expected therapeutic beneﬁt of
TDF in patients with acute-on-chronic liver failure, the design
of a placebo arm in such critically ill patients recruited in
2007–2009 has provoked great concern.
Telbivudine
LdT is an L-nucleoside analogue and has potent antiviral activity
against HBV. A randomized, double-blind, multicenter trial com-Journal of Hepatology 201pared the safety and efﬁcacy of LdT 600 mg (N = 114) with LAM
100 mg (N = 114) daily for 104 weeks in patients with decompen-
sated cirrhosis (CTP score >7) [60]. At week 104, a greater propor-
tion of LdT-treated patients achieved HBV DNA <300 copies/ml
(49% vs. 40%) and ALT normalization (61% vs. 52%) than LAM-trea-
ted patients. The changes in CTP and MELD scores were compara-
ble between LdT and LAM treated patients. Cumulative HCC and
death rates were 15% and 16% for LdT, and 16% and 22% for LAM,
respectively. Severe adverse event rates were comparable
between groups. Cumulatively, 27% of LdT recipients and 36% of
LAM recipients developed genotypic resistance during a 2-year
period. These results showed that LdT was well tolerated with
the efﬁcacy of stabilizing liver function comparable to LAM. How-
ever, both agents were associated with a signiﬁcant rate of viro-
logical breakthrough, which limits their roles as a ﬁrst-line
therapy in this patient population.
Key Points 
• Liver disease may continue to progress and decompen- 
sation or HCC may occur, especially in cases with active 
HBV replication. Decompensation may occur at a rate of 
2-5% per year
• The 5-year survival rate is 84% in patients with compen- 
sated HBV-related cirrhosis, but only 14-35% in patients 
with decompensated cirrhosis
• Oral antiviral agents are safe and effective in restoring liver 
function and improving patient survival, especially if 
therapy is initiated early enough
• The clinical improvement in some wait-listed patients 
with antiviral therapy can result in their withdrawal from 
transplant list
• Considering and drug resistance
entecavir and tenofovir are the drugs for HBV-
related decompensated cirrhosis
• In the era of nucleos(t)ide analogue, interferon is 
contraindicated in this patient population
• The preventive effect of antiviral therapy in HCC 
development has yet to be convincingly demonstrated
efficacy profile,
first-lineConclusions and perspective
Active viral replication at presentation of cirrhosis is an important
factor contributing to further liver disease progression. Decom-
pensation may occur at a rate of 2–5% per year. Once decompen-
sation occurs, the prognosis is poor. Patients with decompensated
cirrhosis should be promptly and adequately treated for the
decompensating events with relevant current standard of care.
Oral antiviral therapy should be instituted regardless of HBV
DNA level as early as possible and liver transplantation should
be considered (Fig. 2). Each of the ﬁve antiviral agents has shown
safety and efﬁcacy in improving hepatic function in this patient
population. Of note, these studies included different patient pop-
ulation with different severity in terms of CTP/MELD scores and
had different aim/design of the trial, as compared in Table 2.2 vol. 57 j 442–450 447
Ascites
SBP
HRS
HCC
surveillance
Esophageal
and/or 
gastric varices
Antiviral therapy
Entecavir
Tenofovir
Standard of care
HBV-related decompensated cirrhosis
Hepatic
encephalopathy
Liver
transplantation
Fig. 2. Management of patients with hepatitis B virus (HBV)-related decom-
pensated liver disease. HCC, hepatocellular carcinoma; HRS, hepatorenal
syndrome; SBP, spontaneous bacterial peritonitis.
ReviewTaking both efﬁcacy and drug resistance proﬁle into account, ETV
and TDF are superior to LAM, LdT, and ADV, and can be considered
as the ﬁrst choice for Nuc-naïve patients with decompensated cir-Table 2. Oral antiviral therapy in HBV-related decompensated cirrhosis.
Study,
[Ref.]
Fontana et al., 
[44]
Schiff et al., 
[53]
Shim
[54]
Drug(s) used LAM ADV ETV
Number of patients 154 226 70
Baseline data
LAM resistance, (%) 0 100 0
HBeAg-positive, (%) 64 43 49
CTP score 
(class B, C, %)
9 (5-14)b
(38, 22)
8.4c
MELD score n.r. n.r. 11.5
HBV DNA level
(log10 copies/ml)
7.6b 7.4b 7.2c
HBV DNA undetectablee, (%) >80 59 89
ALT normalization, (%) n.r. 77 76
↓ CTP score ≥2, (%) n.r. n.r. 49
MELD score ↓ n.r. -2.0b -2.2
1-year survival, (%) 84 86 87
VB or resistance, (%) 27f 2g 0f
Safety issues LAM resistance Nephrotoxicity
6%
n.r.
1-year efficacy and safety data
related flare
ADV, adefovir; ALT, alanine aminotransferase; CTP, Child–Turcotte–Pugh; ETV, entecavi
MELD, model for end stage liver disease; nephrotoxicity: " creatinine of P0.5 mg/dl fro
breakthrough.
aFifty ﬁve patients who survived 1 year were analyzed for efﬁcacy data.
bMedian (range).
cMean.
dETV 0.5 mg for <6-month LAM exposure and no history of LAM resistance mutations, 1
eLower limit of detection (copies/ml): 7  105 [44], 1000 [53], 400 [58], 300 [55,60], 50
fVirological breakthrough.
gResistance.
hNephrotoxicity or serum phosphorus (P) <2 mg/dl.
448 Journal of Hepatology 201rhosis. However, there are concerns about nephrotoxicity [61,62]
and metabolic bone disease observed in human immunodeﬁ-
ciency virus infected patients with TDF treatment [63], although
not conﬁrmed in the 48-week report of the trial in HBV monoin-
fected patients with milder decompensation in terms of baseline
MELD and CTP scores [58]. Given that high rate of drug resistance
will emerge upon long-term use of ETV 1 mg/day in patients with
LAM resistance, TDF is probably a better choice than ETV for LAM
or LdT experienced patients.
The preventive effect of antiviral therapy in HCC development
has yet to be convincingly demonstrated. The continued follow-
up of these ongoing studies will provide more deﬁnite recom-
mendations. Finally, decompensated HBV patients receiving oral
Nuc(s) must undergo frequent clinical and laboratory assessment
to insure medication compliance and surveillance for virological
and clinical response as well as drug side effects, drug resistance,
and HCC [64].Financial support
This study was supported by Grants from Chang Gung Medical
Research Fund (SMRPG 1005, BMRPG 380061) and the Prosper-
ous Foundation, Taipei, Taiwan.a et al., Liaw et al., 
[55]
Liaw et al.,
[58]
Chan et al., 
[60]
 (0.5 mg) ETV/ADV TDF/TDF + FTC/
ETVd
LdT/LAM
100/91 45/45/22 114/114
36/33 18/22/14 0/0
54/55 31/40/32 37/32
8.8/8.4c
(63, 30)/(67, 22)
7/7/7b 8.1/8.5c
c 17.1/15.3c 11/13/10.5b 14.7/15.5c
7.5/8.2c 5.7/6.3/5.9b 7.6/7.6c
57/20 71/88/73 65/61
63/46 46/64/41 65/68
35/27 26/48/42 32/39 
c -2.6/-1.7c -2/-2/-2b -1.0/-2.0b
77/67 96/96/91 94/88
3/7g 0/0/0g 27/36g
Nephrotoxicity
17%/24%
Nephrotoxicityh
9%/7%/5%
Myopathy 
1%/0
r; FTC, emtricitabine; HBV, hepatitis B virus; LAM, lamivudine; LdT, telbivudine;
m baseline; n.r., not reported; TDF, tenofovir disoproxil fumarate; VB, virological
.0 mg for P6-month LAM exposure and/or a history of LAM resistance mutations.
[54].
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